Teva Pharmaceuticals Soars After Buffett's Berkshire Hathaway Discloses Stake
Teva Poised to Face U.S. Charges in Drug Price-Fixing Probe - Bloomberg
Teva shares approach 20-year low amid Moody's warning and other woes | Fierce Pharma
:max_bytes(150000):strip_icc()/TEVA-Chart-02142019-5c65830bc9e77c0001d93394.png "Where Are Teva Shares Headed After the Q4 Decline?")
Where Are Teva Shares Headed After the Q4 Decline?
Why You Should Still Buy Teva (NYSE:TEVA) | Seeking Alpha
Teva Stock Skyrockets After Inking North Of $4 Billion In Opioid Settlements | Investor's Business Daily
Teva Pharmaceutical Industries Ltd. – Artonpapers
Teva Stock Is Still Cheap; Q4 Earnings Should Show Turnaround Progress | investing.com
Teva reaches $15m deal with Louisiana to settle opioid-related claims | The Times of Israel
Teva sees return to growth after opioid settlement, shares jump | Reuters
Teva Pharmaceutical Industries (TEVA) Stock Price, News & Info | The Motley Fool
Teva Shares Rise on Revenue Beat, Guidance; New CFO Named - CFO
Teva shares jump 11 percent after Berkshire reports $358 million stake
Teva Shares Spike After Q1 Earnings Beat, Full Year Forecast Boost - TheStreet
Teva shares plunge as competitors get nod for copycat flagship drug | The Times of Israel
Teva shares fall after US Patent Office invalidates two patents
Teva- Pharmaceutical Industries Ltd. - ADR Shares Near 52-Week High - Market Mover | Nasdaq
Is A Fall Imminent For Teva Stock After Its Recent Rally?
Teva Pharmaceutical | $TEVA Stock | Shares Rally After Winning FDA Approval for Migraine Therapy - Warrior Trading News
With a Deal in Hand, Teva Stock Can Chart a Difficult Comeback | Nasdaq
Teva shares climb after FDA approves its generic EpiPen | Financial Times
Teva reaches $4.35 billion settlement in U.S. opioid lawsuits, shares surge | Ctech
Teva Pharmaceutical: A Holiday Season Sale (NYSE:TEVA) | Seeking Alpha
Teva Pharmaceuticals (TEVA) Stock Gets Upgraded at HSBC - TheStreet
